Bristol Myers Squibb: Rerating Priced In, Patience Will Prove It - Downgrade to Short
Bristol Myers Squibb (BMY) has seen a rapid rerating. The stock now trades at about $54.65 with a 4.5% yield and a mid-teens PE, but elevated leverage, mixed technicals, and limited near-term growth catalysts argue against further multiple expansion. We downgrade to a short trade for the swing-term (45 trading days) with a clear entry, stop and tar…